Atlas Trials

Rituximab-HyperCVAD (R-HCVAD) Alternating With Rituximab-Methotrexate-Cytarabine- (R-MC) in Newly Diagnosed Patients With Diffuse Large B-Cell Lymphoma With MYC-Rearrangement.

Clinical trial NCT01854372 · WITHDRAWN

Trial details

NCT number
NCT01854372
Sponsor
The University of Texas Health Science Center at San Antonio
Status
WITHDRAWN
Phase
Phase 2
Study type
INTERVENTIONAL
Newly Diagnosed Diffuse Large B-Cell LymphomaIntermediate (Burkitt-Like) Lymphoma
Start date
2013-06-01
Primary completion
2013-11-01
Enrollment
0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.